Compare DCI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCI | VALN |
|---|---|---|
| Founded | 1915 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 855.8M |
| IPO Year | 1987 | 2021 |
| Metric | DCI | VALN |
|---|---|---|
| Price | $109.26 | $9.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $98.60 | $15.75 |
| AVG Volume (30 Days) | ★ 766.3K | 13.0K |
| Earning Date | 02-26-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.21 | N/A |
| Revenue | ★ $3,726,200,000.00 | $211,089,992.00 |
| Revenue This Year | $4.69 | $3.64 |
| Revenue Next Year | $4.94 | $12.23 |
| P/E Ratio | $34.29 | ★ N/A |
| Revenue Growth | 2.37 | ★ 13.48 |
| 52 Week Low | $57.45 | $5.43 |
| 52 Week High | $112.84 | $12.25 |
| Indicator | DCI | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 75.35 | 58.89 |
| Support Level | $109.74 | $9.53 |
| Resistance Level | $112.84 | $10.40 |
| Average True Range (ATR) | 2.09 | 0.28 |
| MACD | 0.33 | 0.04 |
| Stochastic Oscillator | 80.46 | 77.92 |
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.